THE COST-EFFECTIVENESS OF TAVI IN INOPERABLE AND HIGH RISK PATIENTS IN FRANCE

被引：0
|
作者：
Goodall, G. [1 ]
Zemanova, B. [2 ]
Candolfi, P. [1 ]
Sohlberg, A. [1 ]
机构：
[1] Edwards Lifesci, Nyon, Switzerland
[2] Edwards Lifesci, Irvine, CA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1080
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMD96
引用
收藏
页码：A589 / A589
页数：1
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF TAVI IN INTERMEDIATE RISK PATIENTS IN FRANCE
    Goodall, G.
    Candolfi, P.
    Zemanova, B.
    Sohlberg, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A588 - A588
  • [2] COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) IN HIGH-RISK OR INOPERABLE PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN SPAIN
    Ferreira-Gonzalez, I
    Serra, V
    Abdul, O.
    Lizan, L.
    Paz, S.
    Banz, K.
    Sureda, C.
    Igual, A.
    Garcia del Blanco, B.
    Angel, J.
    Garcia-dorado, D.
    Tornos, P.
    Ribera, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A248 - A249
  • [3] Tools and Techniques - Statistics: Comments on a cost-effectiveness study of TAVI for patients with inoperable aortic stenosis
    Redekop, W. Ken
    Kahlert, Philipp
    Pregowski, Jerzy
    Ramcharitar, Steve
    Naber, Christoph
    [J]. EUROINTERVENTION, 2014, 9 (10) : 1241 - 1243
  • [4] COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR HIGH-RISK PATIENTS IN CHILE
    Paredes, D.
    Ryschon, A. M.
    Pietzsch, J. B.
    Valencia, J.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S104 - S104
  • [5] COST-EFFECTIVENESS OF HIGH DOSE HAEMODIALYSIS IN FRANCE
    Benain, Jean-Philippe
    Galland, Roula
    Kessler, Michele
    Lobbedez, Thierry
    Fagnani, Francis
    Dumas, Jean-Jacques
    Chauvet, Veronique
    Laville, Maurice
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [6] The cost-effectiveness of preoperative optimisation of high risk surgical patients
    AN Chamberlain
    N Harper
    S Morris
    [J]. Critical Care, 6 (Suppl 1):
  • [7] COST-EFFECTIVENESS OF ALIROCUMAB FOR PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CV RISK
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2019, 22 : S128 - S128
  • [8] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [9] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
  • [10] Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients
    Goodall, Gordon
    Lamotte, Mark
    Ramos, Mafalda
    Maunoury, Franck
    Pejchalova, Barbora
    de Pouvourville, Gerard
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 289 - 296
12345